Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment;Wybrane mechanizmy terapeutycznego oddziaływania trójtlenku arsenu w leczeniu nowotworów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 463-467

  Izdebska, Magdalena ^a   Grzanka, Alina ^a   Szczepański, Mariusz Andrzej ^a   Litwiniec, Anna ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Apoptosis; Arsenic trioxide; Glutathione; JNK; NF B

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASCORBIC ACID; CASPASE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID; SIGNAL PEPTIDE;

DRUG COMBINATION; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; ARSENICALS; ASCORBIC ACID; CASPASES; DRUG THERAPY, COMBINATION; GLUTATHIONE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE KINASE 4; NEOPLASMS; NF-KAPPA B; OXIDES; TRETINOIN;

EID: 58149374102     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Antman K.H.: Introduction: The history of arsenic trioxide in cancer therapy. Oncologist, 2001; 6 (Suppl.2): 1-2
2. Aronson S.M.: Arsenic and old myths. R. I. Med., 1994; 77: 233-234
3. Bilska A., Kryczyk A., Wodek L.: Róne oblicza biologicznej roli glutationu. Post. Hig. Med. Dow., 2007; 61: 438-453
4. Bornstein J., Sagi S., Haj A., Harroch J., Fares F.: Arsenic trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol. Oncol., 2005; 99: 726-729
5. Chen G.Q., Zhu J., Shi X.G., Ni J.H., Zhong H.J., Si G.Y., Jin X.L., Tang W., Li X.S., Xong S.M., Shen Z.X., Sun G.L., Ma J., Zhang P., Zhang T.D., Gazin C., Naoe T., Chen S.J., Wang Z.Y., Chen Z.: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 1996; 88: 1052-1061
6. Chow S.K., Chan J.Y., Fung K.P.: Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J. Cell Biochem., 2004; 93: 173-187
7. Czarnecka A.M., Golik P., Bartnik E.: Mitochondria jako integratory apoptozy. Post. Biol. Kom., 2006; 33: 525-541
8. Davison K., Mann K.K., Waxman S., Miller W.H. Jr.: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood, 2004; 103: 3496-3502
9. Fox E., Razzouk B.I., Widemann B.C., Xiao S., O'Brien M., Goodspeed W., Reaman G.H., Blaney S.M., Murgo A.J., Balis F.M., Adamson P.C.: Phase I trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood, 2008; 111: 566-573
10. Gensini G.F., Conti A.A., Lippi D.: The contributions of Paul Ehrlich to infectious disease. J. Infect., 2007; 54: 221-224
11. Germolec D.R., Spalding J., Yu H.S., Chen G.S., Simeonova P.P., Humble M.C., Bruccoleri A., Boorman G.A., Foley J.F., Yoshida T., Luster M.I.: Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol., 1998; 153: 1775-1785
12. Grad J.M., Bahlis N.J., Reis I., Oshiro M.M., Dalton W.S., Boise L.H.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001; 98: 805-813
13. Grdzka I.: Apoptoza. Decyzja naley do mitochondrium. Post. Biochem., 2000; 46: 2-16
14. Hayashi T., Hideshima T., Akiyama M., Richardson P., Schlossman R.L., Chauhan D., Munshi N.C., Waxman S., Anderson K.C.: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol. Cancer Ther., 2002; 1: 851-860
15. Ishitsuka K., Ikeda R., Utsunomiya A., Uozumi K., Hanada S., Suzuki S., Takeuchi S., Takatsuka Y., Takeshita T., Ohno N., Arima T.: Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor a receptor independent caspase activation. Leuk. Lymphoma, 2002; 43: 1107-1114
16. JóYwiak Z., Marczak A.: Rola kanaów jonowych w procesie apoptozy. Post. Biochem., 2006; 52: 373-382
17. Kerbauy D.M., Lesnikov V., Abbasi N., Seal S., Scott B., Deeg H.J.: NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood, 2005; 106: 3917-3925
18. Kiliañska Z.M., Mikiewicz A.: Kaspazy krêgowców; ich rola w przebiegu apoptozy. Post. Biol. Kom., 2003; 30: 129-152
19. Kim H.R., Kim E.J., Yang S.H., Jeong E.T., Park C., Kim S.J., Youn M.J., So H.S., Park R.: Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int. J. Oncol., 2006; 28: 1401-1408
20. Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., Naoe T.: Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia, 2000; 14: 1743-1750
21. LeBlanc H.N., Ashkenazi A.: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ., 2003; 10: 66-75
22. Liu Q., Hilsenbeck S., Gazitt Y.: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood, 2003; 101: 4078-4087
23. abêdzka K., Grzanka A., Izdebska M.: Mitochondriom a mieræ komórki. Post. Hig. Med. Dow., 2006; 60: 439-446
24. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., Bommert K., Dorken B.: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood, 2003; 102: 1028-1034
25. Miller W.H.Jr., Schipper H.M., Lee J.S., Singer J., Waxman S.: Mechanisms of action of arsenic trioxide. Cancer Res., 2002; 62: 3893-3903
26. Muscarella D.E., Bloom S.E.: Differential activation of the c-Jun Nterminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol. Sci., 2002; 68: 82-92
27. Powell B.L.: Acute progranulocytic leukemia. Curr. Opin. Oncol., 2001; 13: 8-13
28. Shao Q.S., Ye Z.Y., Ling Z.Q., Ke J.J.: Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J. Gastroenterol., 2005; 11: 3451-3456
29. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., PandolfiP.P., Warrell R.P. Jr.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 1998; 339: 1341-1348
30. Stêpieñ A., Izdebska M., Grzanka A.: Rodzaje mierci komórki. Post. Hig. Med. Dow., 2007; 61: 420-428
31. Tallman M.S., Nabhan C., Feusner J.H., Rowe J.M.: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood, 2002; 99: 759-767
32. Tan B., Huang J.F., Wei Q., Zhang H., Ni R.Z.: Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J. Gastroenterol., 2005; 11: 5938-5943
33. Tarkanyi I., Dudognon C., Hillion J., Pendino F., Lanotte M., Aradi J., Segal-Bendirdjian E.: Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia, 2005; 19:1806-1811
34. Uslu R., Sanli U.A., Sezgin C., Karabulut B., Terzioglu E., Omay S.B., Goker E.: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res., 2000; 6: 4957-4964
35. Vahidnia A., van der Voet G.B., de Wolff F.A.: Arsenic neurotoxicity-A review. Hum. Exp. Toxicol., 2007; 26: 823-832
36. Verma U.N., Yamamoto Y., Prajapati S., Gaynor R.B.: Nuclear role of I kappa B kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression. J. Biol. Chem., 2004; 279: 3509-3515
37. Waxman S., Anderson K.C.: History of the development of arsenic derivatives in cancer therapy. Oncologist, 2001; 6 (Suppl.2): 3-10
38. Yang C.H., Kuo M.L., Chen J.C., Chen Y.C.: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. J. Cancer, 1999; 81: 796-799
39. Zhu J., Okumura H., Ohtake S., Nakamura S., Nakao S.: Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol. Rep., 2003; 10: 705-709